203. 22q11.2 deletion syndrome Clinical trials / Disease details
Clinical trials : 5 / Drugs : 7 - (DrugBank : 1) / Drug target genes : 14 - Drug target pathways : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02895906 (ClinicalTrials.gov) | November 28, 2016 | 29/8/2016 | Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions | A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD) | 22q11.2 Deletion Syndrome | Drug: NFC-1 | Aevi Genomic Medicine | NULL | Completed | 12 Years | 17 Years | All | 2 | Phase 1 | United States |